Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected By NIH/NIAID Project NextGen For Inclusion In Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals' vaccine candidate, TNX-1800, has been selected by the National Institute of Allergy and Infectious Diseases (NIAID) for inclusion in early phase clinical trials. The trials are part of the Project NextGen initiative, aimed at developing the next generation of vaccines and therapeutics for COVID-19. The Phase 1 clinical trial of TNX-1800 is expected to start in the second half of 2024, with NIAID covering the full cost of the trial. Tonix will supply the vaccine candidate.
November 02, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' vaccine candidate, TNX-1800, has been selected for early phase clinical trials by NIAID. This could potentially boost the company's profile and stock value if the trials prove successful.
The selection of Tonix Pharmaceuticals' vaccine candidate for early phase clinical trials by a reputable institution like NIAID is a positive development for the company. If the trials prove successful, it could significantly boost the company's profile and stock value. However, the trials are still in the early phase and the outcome is uncertain.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100